Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

BACKGROUND: Anti-PD-1 monotherapy is the standard therapy for advanced melanoma patients, including those with NRAS mutations. The influence of NRAS mutation on immunotherapy, especially in noncutaneous melanoma, is largely uncharacterized. MATERIALS AND METHODS: We analyzed clinical data of four cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Li, Wang, Xuan, Chi, Zhihong, Sheng, Xinan, Kong, Yan, Mao, Lili, Lian, Bin, Tang, Bixia, Yan, Xieqiao, Bai, Xue, Li, Siming, Guo, Jun, Cui, Chuanliang, Si, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289467/
https://www.ncbi.nlm.nih.gov/pubmed/34290710
http://dx.doi.org/10.3389/fimmu.2021.691032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289467/
https://www.ncbi.nlm.nih.gov/pubmed/34290710
http://dx.doi.org/10.3389/fimmu.2021.691032

Ejemplares similares